Lataa...
Efficacy of Guanfacine Extended Release in the Treatment of Combined and Inattentive Only Subtypes of Attention-Deficit/Hyperactivity Disorder
BACKGROUND: Extended-release guanfacine (GXR) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6–17 years. This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness. METHOD: Data from t...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Mary Ann Liebert, Inc.
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3373219/ https://ncbi.nlm.nih.gov/pubmed/22612526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2010.0135 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|